3342 completed, 381 recruiting, 370 active not recruiting, 365 terminated. 1244 Phase 1, 1112 Phase 2, 974 Phase 3, 356 Phase 4, 141 Not applicable.
Follow AstraZeneca: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records Lung Cancer | Not yet recruiting | AstraZeneca | 3000 | 2027-04-01 | 2026-06-02 | |
| Optimizing Care For Management Of Hard To Control Hypertension In Low-Income Patients Across Family Health Centers In New York City Multilevel Hypertension Care Model - Hypertension | Not applicable | Not yet recruiting | NYU Langone Health | 628 | 2027-02-01 | 2026-07-14 |
| Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 1 | Suspended | University of Maryland, Baltimore | 50 | 2027-01-30 | 2026-09-14 |
| Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome) Benralizumab 30 MG/ML [Fasenra], Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride - DRESS Syndrome | Phase 2 | Not yet recruiting | University Hospital, Lille | 96 | 2027-01-06 | 2026-05-15 |
| Observational Study That Will Analyse the Spread and Stratification of Lung Cancer Risk Using Artificial Intelligence Lung Cancer | Not yet recruiting | AstraZeneca | 1500 | 2026-12-30 | 2026-10-23 | |
| variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway Chronic Lymphocytic Leukemia, Haematological Malignancy | Not yet recruiting | The Royal Wolverhampton Hospitals NHS Trust | 130 | 2026-12-01 | 2026-09-15 | |
| Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 20 | 2026-12-01 | 2026-10-28 |
| A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial Educational Intervention, Survey Administration, Interview - Lung Carcinoma | Not applicable | Recruiting | Fred Hutchinson Cancer Center | 45 | 2026-12-01 | 2026-10-29 |
| A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. FLOT Chemotherapy, Durvalumab - Gastric, Esophagogastric Junction | Phase 3 | Not yet recruiting | AstraZeneca | 140 | 2026-11-30 | 2026-10-16 |
| A Study to Evaluate Treatment Patterns and Investigate Adult Patients With B-cell Lymphoma Lymphoma, B-Cell | Not yet recruiting | AstraZeneca | 532 | 2026-11-30 | 2026-10-20 | |
| A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC IMFINZI - Carcinoma, Non-Small-Cell Lung | Not yet recruiting | AstraZeneca | 78 | 2026-11-30 | 2026-10-30 | |
| Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea Severe Asthma, Chronic Rhinosinusitis With Nasal Polyps(CRSwNP) | Not yet recruiting | AstraZeneca | 210 | 2026-11-28 | 2026-06-04 | |
| Saruparib in HRDsig+ Solid Tumors Saruparib, FoundationOne®CDx - Malignant Neoplastic Disease (Disorder) | Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 124 | 2026-11-01 | 2026-09-22 |
| Impact of Multidisciplinary Care, Structured and Targeted on the COPD Patient's Clinical Pathway. COPD targeted pharmaceutical interview and consultation, Respiratory Insufficiency Day Hospitalization, Pulmonary Function Test - Chronic Obstructive Pulmonary Disease, Lung Diseases, Obstructive | Not applicable | Not yet recruiting | Centre Hospitalier Universitaire de Nīmes | 116 | 2026-11-01 | 2026-10-30 |
| China CRSwNP Registry Study Routine Clinical Care for CRSwNP - Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Not yet recruiting | Beijing Tongren Hospital | 1000 | 2026-10-31 | 2026-08-31 | |
| GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study) Gastric Cancer, Gastroesophageal Junction Cancer | Not yet recruiting | AstraZeneca | 300 | 2026-10-31 | 2026-10-20 | |
| Lung Cancer Screening Implementation Project in the Brazilian Public Health Care System (LUSIP) Lung Cancer | Not yet recruiting | AstraZeneca | 477 | 2026-10-30 | 2026-09-11 | |
| Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing NSAI + CDK4/6i, NSAI + CDK4/6i + Capivasertib, Fulvestrant + CDK4/6i + Capivasertib - HR Positive/HER-2 Negative Breast Cancer | Phase 3 | Not yet recruiting | SWOG Cancer Research Network | 1084 | 2026-10-30 | 2026-09-03 |
| Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV) Anifrolumab: SC formulation via AI, Anifrolumab: IV formulation, Anifrolumab: SC formulation via aPFS - Systemic Lupus Erythematosus | Phase 1 | Not yet recruiting | AstraZeneca | 92 | 2026-10-30 | 2026-07-07 |
| A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-Invasive Durvalumab, Gemcitabine, Cisplatin - Muscle-Invasive Bladder Cancer (MIBC) | Phase 4 | Not yet recruiting | AstraZeneca | 50 | 2026-10-20 | 2026-10-15 |
Showing 20 of 4818. Sign in to see all of them.
Diabetes Mellitus, Type 2 (382) · Asthma (359) · Carcinoma, Non-Small-Cell Lung (317) · Breast Neoplasms (295) · Pulmonary Disease, Chronic Obstructive (283) · Neoplasms (146) · Diabetes Mellitus (138) · Lung Neoplasms (124) · Prostatic Neoplasms (104) · Gastroesophageal Reflux (98) · Schizophrenia (95) · Ovarian Neoplasms (94) · Neoplasm Metastasis (91) · Heart Failure (83) · Hypertension (74)
durvalumab (358) · dapagliflozin (182) · olaparib (169) · tremelimumab (124) · Carboplatin (122) · Cisplatin (113) · Gefitinib (112) · Rosuvastatin Calcium (110) · Budesonide (106) · Esomeprazole (103) · Quetiapine Fumarate (102) · Ticagrelor (86) · Paclitaxel (82) · osimertinib (77) · Exenatide (75)
United States (1904) · United Kingdom (948) · Germany (735) · Canada (690) · Spain (682) · France (596) · Japan (570) · South Korea (551) · Italy (520) · China (508) · Poland (459) · Australia (384) · Taiwan (372) · Netherlands (363) · Sweden (356)
Esther Garcia, MD (19) · Lisa Porter, MD (19) · Paula Fernstrom (18) · James Malone, MD (17) · Toshimitsu Tokimoto (16) · Mark Sostek, MD (15) · Catherine Bonuccelli (12) · Jane Robertson, BSc, MBCHB, MD (12)
PMID 38770818, PMID 22236356, PMID 22913891, PMID 26894924, PMID 27402391, PMID 40311309, PMID 24816198, PMID 29856004, PMID 32306296, PMID 35170751, PMID 23748506, PMID 24067192, PMID 24175720, PMID 26474010, PMID 26961146, PMID 34473343, PMID 36005278, PMID 23922302, PMID 24408516, PMID 25889498, PMID 27033025, PMID 27160944, PMID 28878934, PMID 29536781, PMID 34904813, PMID 35713300, PMID 37185961, PMID 39695768, PMID 40913594, PMID 42551404, PMID 20102307, PMID 22329608, PMID 23485955, PMID 23497790, PMID 23795975, PMID 27461213, PMID 28419462, PMID 33368935, PMID 35224730, PMID 36472162, PMID 38018702, PMID 38682786, PMID 42476723, PMID 17705687, PMID 19196892, PMID 19238149, PMID 19451554, PMID 21225239, PMID 21309844, PMID 21680990
2023 (116), 2018 (56), 2019 (47), 2025 (42), 2015 (41), 2014 (39), 2017 (36), 2016 (31), 2008 (17), 2009 (13), 2005 (8), P30CA015704 (4), 2004 (3), P30CA006516 (2), 1UH3TR001372-01 (1)